Roivant Sciences ROIV
NASDAQ ROIV
$40.99 +0.32 (+0.79%)
As of: Nov 10, 2026 · 2:20 PM EST

Roivant Sciences (ROIV) Notes Payables (2022)

Updated

Roivant Sciences (ROIV) recorded Notes Payables of $33.3 million in fiscal Q1 2023 (quarter ended Jun 30, 2022).

Analysis

Roivant Sciences (ROIV) Notes Payables (2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn
10 Roivant Sciences 28.91 Bn 11.86 Bn 1.16 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2022 33.30 Mn
API Access

Roivant Sciences Notes Payables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=notes-payables&ticker=ROIV&period=max&api_key=YOUR_API_KEY